1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
48.96%
Cash & equivalents changing by 48.96% while Drug Manufacturers - Specialty & Generic maintains stable levels. Benjamin Graham would examine if this divergence is justified.
No Data
No Data available this quarter, please select a different quarter.
48.96%
Cash + STI yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
4.62%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
-10.16%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
No Data
No Data available this quarter, please select a different quarter.
15.48%
Current assets growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a potential liquidity edge if well allocated.
-3.35%
PP&E growth below half of Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
-6.84%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-16.42%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-10.19%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-89.13%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.32%
Below half the Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
-6.35%
Below half the Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see potential stagnation or distress vs. peers.
-2.34%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-1.97%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
11.21%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
32.89%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
-40.61%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-0.74%
Below half Drug Manufacturers - Specialty & Generic median of 1.42%. Joel Greenblatt sees more conservative short-term leverage than peers.
-16.46%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
-17.10%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
-34.59%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-16.90%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-12.96%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
10.42%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-98.64%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects poor profitability or large dividend drains.
-2155.84%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-4.94%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -0.05%. Joel Greenblatt sees stronger equity growth vs. peers.
-6.35%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a major slowdown or distress.
-89.13%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-14.88%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-54.17%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
